FDA Warns Enessa For Claims Violations, Diminish-Rosacea Treatment
This article was originally published in The Rose Sheet
Executive Summary
Natural brand Enessa may have to discontinue or relabel its Diminish-Rosacea Treatment, as the name constitutes an unapproved drug claim, FDA suggests in a warning letter. Other claims cited by the agency pertain to cellular repair, collagen synthesis, anti-inflammatory benefits and improved micro-circulation.
You may also be interested in...
‘Ant-type Insects’ And Expired Ingredients: FDA Warns Bioque Following Inspection
Agency inspectors observed a range of insanitary conditions and practices at the Blacksburg, Virginia-based manufacturing site that turns out Bioque and Vouray skin-care products, causing the products to be adulterated, according to an FDA warning letter.
FDA’s July Warning Letters To Skin-Care Marketers Continue To Surface
Add Menscience Androceuticals, La Bella Figura and Healing Scents to the list of skin-care marketers hit with FDA warning letters in July. The agency’s policy is to wait for warning letter recipients to acknowledge receipt before posting the communications to its website.
Bragg Live Wants Consumers To Know Efficacy Differs Among Apple Cider Vinegar Formats
Bragg Live says its survey highlights misconceptions consumers have concerning health benefits and efficacy of different delivery formats of apple cider vinegar.